Role of FoxO transcription factors in aging and age-related metabolic and neurodegenerative diseases

Shuqi Du and Hui Zheng*

Abstract
Aging happens to all of us as we live. Thanks to the improved living standard and discovery of life-saving medicines, our life expectancy has increased substantially across the world in the past century. However, the rise in lifespan leads to unprecedented increases in both the number and the percentage of individuals 65 years and older, accompanied by the increased incidences of age-related diseases such as type 2 diabetes mellitus and Alzheimer’s disease. FoxO transcription factors are evolutionarily conserved molecules that play critical roles in diverse biological processes, in particular aging and metabolism. Their dysfunction is often found in the pathogenesis of many age-related diseases. Here, we summarize the signaling pathways and cellular functions of FoxO proteins. We also review the complex role of FoxO in aging and age-related diseases, with focus on type 2 diabetes and Alzheimer’s disease and discuss the possibility of FoxO as a molecular link between aging and disease risks.

Keywords: Aging, FoxO, Age-related disease, Type 2 diabetes mellitus, Alzheimer’s disease

Introduction
The FoxO transcription factor family belongs to the Forkhead box transcription factors consisting of DAF-16 in Caenorhabditis elegans, dFOXO in Drosophila Melanogaster, and four members in mammals: FoxO1, FoxO3, FoxO4 and FoxO6. FoxO proteins receive and integrate various upstream signals and, through post-translational modifications and cytoplasmic-to-nucleus trafficking, transcriptionally control a wide range of downstream targets in both peripheral tissues and the central nervous system (CNS). Of particular significance, FoxO is an integral component of the insulin and insulin-like growth factor signaling pathway that plays essential and evolutionarily conserved functions in cellular metabolism, aging and longevity. Dysfunction of this pathway is a major cause of type 2 diabetes mellitus (T2DM), a metabolic disorder influenced by age. Interestingly, accumulating evidence indicates that T2DM is associated with an increased risk of developing Alzheimer’s disease (AD), which is the most common cause of dementia in the elderly. Recognized as a neurodegenerative disorder, AD is also accompanied by significant metabolic disturbances in the brain. Given its prominent role in metabolic homeostasis and organismal longevity, misregulation of the FoxO signaling pathway may underlie both age-associated functional decline and age-related diseases. This review highlights the diverse functions of FoxO in physiology, aging and disease. We will start by describing the molecular characteristics of the FoxO proteins, followed by their cellular signaling pathways and associated activities. Next we will review their physiological functions, with particular emphasis on aging and lifespan regulation across species and CNS function in the mammalian system. Lastly we will summarize the published literature highlighting a critical role of FoxO in age-associated...
metabolic and neurodegenerative diseases, in particular T2DM and AD, and provide our perspective on how these two diseases with distinct clinical presentations may be connected through FoxO signaling and regulation.

**FoxO transcription factors**

**FoxO proteins and functional domains**

The FoxO proteins have a conserved winged-helix DNA-binding domain (DBD) known as the Forkhead domain. They bind to DNA duplexes as monomers and recognize two consensus sequences, the DAF-16 family member-binding element (DBE) 5′-GTAAA(T/C)AA-3′ and the insulin responsive element (IRE) 5′-(C/A)(A/C) AAA(C/T)AA-3′ [1]. In addition to the DBD, FoxO proteins also carry a nuclear localization signal, a nuclear export signal, and a C-terminal transactivation domain (Fig. 1). These functional structures together with numerous post-translational modifications (PTMs) tightly control FoxO’s subcellular localization and transcription activity and afford its sophisticated regulation of various biological processes.

**FoxO signaling pathways**

FoxO activity is mainly regulated by its PTMs and subsequent subcellular translocation between the cytosol and the nucleus, where it transcriptionally controls a wide range of downstream targets. In addition, FoxO PTMs also influence its binding affinity with its cofactors, resulting in distinct transcription profiles [9]. Two evolutionarily conserved pathways exist to regulate FoxO activities in cells (Fig. 2). The canonical insulin and growth factor signaling initiates when secreted insulin or insulin-like growth factors (IGFs) bind to their cell surface receptors. Dimerized receptors trigger a series of autophosphorylation and recruit insulin receptor substrate 1–4 (IRS1-4) and phosphatidylinositol 3-kinase (PI3K), the latter increases the local concentrations of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 acts as a second messenger to activate phosphoinositide-dependent kinase 1 (PDK1) and protein kinase B (AKT or PKB). Active AKT translocates to the nucleus and phosphorylates FoxO at three conserved residues, enhancing the binding of FoxO proteins to 14-3-3 and leading to their cytoplasmic localization. Inactivation of FoxO favors cellular growth under normal conditions. The other pathway involves FoxO's

![Fig. 1](image-url) Structural domains of FoxO proteins across species. Members in FoxO family share a highly conserved forkhead DNA-binding domain (DBD), a nuclear localization signal (NLS), one or two nuclear export signal (NES), and a transactivation domain (TAD). FoxO6 does not have a functional NES. The positions of Akt phosphorylation sites are indicated by circles. The first two phosphorylation sites also serve as binding motifs for 14-3-3 protein [2-8].
role in stress response. When cells are in a stressed condition, such as increasing levels of reactive oxygen species (ROS), c-Jun N-terminal kinase (JNK) is activated and phosphorylates cytoplasmic FoxO. This stimulatory phosphorylation induces the release of FoxO from 14-3-3 and upregulates its transcriptional activity. Importantly, the opposing regulation of FoxO activity by insulin/IGF pathway and JNK pathway is evolutionarily conserved in *C. elegans*, *Drosophila* and vertebrates [10, 11].

In addition to the two well-established mechanisms described above, numerous other signaling events affect FoxO activity. For example, AMP-activated protein kinase (AMPK), an enzyme stimulated by a high AMP to ATP ratio, phosphorylates and activates FoxO for stress resistance [12]. Surprisingly, this phosphorylation event of FoxO does not alter their subcellular localization. Meanwhile, cyclin-dependent kinases (CDKs) activates FoxO to control the expression of many essential cell cycle components during proliferation [13, 14]. Furthermore, regulation of FoxO activities by ataxia telangiectasia mutated (ATM) and ATM Rad3-related (ATR) proteins have been reported in response to DNA damage [15]. However, the regulation of FoxO goes beyond phosphorylation. In fact, other PTMs are also involved to modulate FoxO functions. The effect of acetylation on FoxO proteins is controlled by the histone acetyltransferases and histone deacetylases (HDACs). Studies have shown that HDAC-mediated deacetylation of FoxO leads to its nuclear translocation and transcriptional activation under nutrient deprivation [16]. On the other hand, the degradation of cytoplasmic FoxO proteins rely on the ubiquitin–proteasome pathway. E3 ubiquitin ligase S-phase kinase associated protein 2 (SKP2) and mouse double minute 2 homolog (MDM2) recognizes FoxO with certain inhibitory phosphorylation or acetylation signals and induces their polyubiquitination for degradation [17, 18]. Under stress conditions like accumulative ROS in cells, MDM2 promotes FoxO mono-ubiquitination as well [19]. Instead of promoting degradation, this modification has a stimulatory effect on FoxO. Lastly, methylation by protein arginine methyltransferase 1/6 (PRMT1/6) and O-GlcNAcylation by O-GlcNAc transferase (OGT) have been characterized to impact FoxO activity by blocking the addition of other functional PTMs, adding another layer of complexity to FoxO regulation [20–23].

**Cellular functions of FoxO**

Since their first identification as chromosomal translocation partners in acute myeloid leukemia and alveolar rhabdomyosarcomas, FoxO functions have been extensively studied in cell culture systems [25, 26]. These efforts revealed FoxO as versatile regulators of many essential cellular processes including metabolism, autophagy, cell cycle arrest, DNA damage repair, apoptosis as well as oxidative stress resistance (Fig. 3). Importantly, although FoxO proteins share highly conserved consensus binding sequences, they not only exhibit distinct regulatory features, but also show high cell-type specificity. As most other transcription factors, the binding of FoxO to coactivators or corepressors and the binding of these complexes to other gene regulators ultimately determine the
outcome of the gene regulation. In consistency, knockout studies of FoxO members revealed distinct phenotypes. Deletion of Foxo1 leads to embryonic lethality due to defects in angiogenesis during early development. Foxo3 knockout mice are viable, but females become infertile after 15 weeks because of the premature primordial follicle activation and subsequent depletion. Foxo6 deficiency attenuates hepatic gluconeogenesis and impairs memory consolidation. Loss of Foxo4, however, does not result in overt anomalies in mice [27, 28]. Therefore, it is crucial to delineate individual FoxO functions in a context-dependent manner [29].

FoxO regulation of metabolism

Insulin is a peptide hormone secreted by beta cells in the pancreatic islets under high blood glucose conditions. It has a potent effect on promoting the cellular uptake and utilization of glucose and stimulating anabolic pathways like glycogenesis, lipogenesis, and protein synthesis. As a critical downstream effector of the insulin signaling pathway, FoxO proteins respond to the changing nutrients and regulate the metabolic homeostasis in various tissues and organs. Liver is highly sensitive to insulin and its proper physiological function depends on Foxo's regulation. In hepatocytes, active Foxo1, Foxo3 and Foxo6 induce the expression of two key enzymes in gluconeogenesis, glucose-6-phosphatase (G6Pase) and phosphoenolpyruvates carboxykinase (PEPCK) [30–34]. Consistently, knockout of either Foxo1 alone or Foxo1/3/4 altogether specifically in mouse liver leads to lower blood glucose levels under both fasting and non-fasting conditions [35, 36]. Foxo6 germline knockout mice also exhibit reduced levels of fasting and non-fasting blood glucose [28]. Additionally, FoxO proteins inhibit glycolysis through suppression of glucokinase and pyruvate kinase gene expression [37, 38]. Taken together, liver FoxO contributes to the maintenance of normal blood glucose. Furthermore, FoxO1 is activated in skeletal muscle following strong stress conditions such as starvation, streptozotocin-induced diabetes, or exercise, where it induces the expression of pyruvate dehydrogenase kinase 4 (PDK4) to conserve glucose and gluconeogenesis substrate and decrease the glycolytic flux during energy deprivation [39–41].
Besides glucose metabolism, FoxO also plays an important role in lipid homeostasis by regulating lipogenesis, fatty acid oxidation, lipid transport and cholesterol metabolism. FoxO1 transcriptionally suppresses the lipogenic master regulator sterol regulatory element binding protein 1c (SREBP1c) in the liver and regulates the expression of several genes in fatty acid biosynthesis pathway such as fatty acid synthase, acetyl-CoA carboxylase alpha and stearoyl-CoA desaturase 1 (Scd1) [42–44]. As well, FoxO activates the expression of lipolysis and fatty acid oxidation genes including lipoprotein lipase (LPL) and carnitine palmitoyltransferase-1 (CPT1) [40, 44]. Interestingly, FoxO can also promote breakdown of lipid droplets through lipophagy, an autophagy subtype that selectively targets lipid contents, by inducing the transcription of autophagy-related genes like ATG5, ATG12, ATG14 and BECN1 [45, 46]. In addition, FoxO1 drives the secretion of liver triglycerides into plasma. It is achieved by direct promoter binding and transcriptionally elevating the expression of apolipoprotein Apo-C-III [47, 48]. On the other hand, fatty acid uptake and subsequent oxidation are under the control of FoxO1 in muscle cells, where its expression alters the subcellular distribution of fatty acid translocase (FAT/CD36) [49]. In line with the regulation of the fatty acid pathway, FoxO3 suppresses the expression of SREBP-2, the master regulator of cholesterol biosynthesis [50]. It can also promote the low-density lipoprotein (LDL)-cholesterol breakdown by downregulating the level of proprotein convertase subtilisin/kexin type 9 (PCSK9) to preserve the LDL receptor (LDLR)-mediated clearance activity [51]. Meanwhile, FoxO1 regulates cholesterol conversion to bile acids by modulating bile acid biosynthetic genes like CYP7A1 and CYP8B1 [52, 53].

The impact of FoxO on metabolic regulation goes beyond peripheral organs. Researchers have observed FoxO1 expression in hypothalamus, the food intake control center in the brain, where it regulates the expression of neuropeptides and affects appetite. It receives and integrates signals of nutritional status and responds by the release of neuropeptides, such as proopiomelanocortin (POMC) and agouti-related peptides (AgRP) [54]. Within the hypothalamus, the arcuate nucleus (ARC) is the “first-order center” for food intake regulation. It contains two groups of neurons, anorexigenic POMC neurons and orexigenic AgRP neurons [55]. FoxO1 is expressed in both types of neurons, and it is located in the nucleus during starvation but translocated to the cytoplasm after feeding [56]. FoxO1 stimulates appetite by direct promoter binding to Agrp and Pomc genes, with an activation effect on AgRP but inhibiting POMC expression [57, 58]. Consistent with this finding, mice with a hypothalamic-specific knock-in allele overexpressing Foxo1 showed increased food intake and decreased energy expenditure [59].

**FoxO regulation of autophagy**

Autophagy is an evolutionarily conserved self-degradative process through which damaged organelles or macromolecules are broken down and recycled within the cell. Autophagy provides cells with alternative energy sources at critical times during development or under nutrient stress, maintains cellular proteostasis, and eliminates invading pathogens. Three forms of autophagy have been identified based on the way cellular components are sequestered and degraded. Microautophagy is characterized by direct lysosomal engulfment of cytoplasmic molecules. Chaperon-mediated autophagy is a selective degradation pathway which involves HSC70-dependent chaperone recognition of specific cargo proteins and subsequent delivery to the lysosome compartment. Macroautophagy (herein referred to as autophagy) is the most well-studied form and it encapsulates cytoplasmic materials with a special structure called autophagosome that fuses with lysosome for cargo degradation. The autophagy process is divided into different stages based on the presence of some featured structures. Upon activation, autophagy is initiated with the formation of a crescent-shaped double-membrane structure called phagophore. Phagophore grows around and sequesters target components and becomes an autophagosome. The autophagosome then fuses with a lysosome and turns into an autolysosome, where sequestered contents are degraded. The successful completion of these sequential steps involves a number of conserved autophagy-related (ATG) proteins and other autophagy regulators [60].

The autophagy regulatory role of the FoxO family was first described in studies of muscle atrophy in murine models, in which FoxO1 and FoxO3 were found to elevate the autophagic flux by increasing the expression of autophagy genes such as Ulk2, Beclin1, Lc3b, Atg12, GabarapL1 and Bnip3 [61, 62]. Besides its transcriptional activity, Zhao and colleagues demonstrated that cytosolic FoxO1 was responsible for the autophagy induction in human cancer cell lines under oxidative stress or serum starvation. Specifically, SIRT2 acetylates FoxO1 upon stress and the acetylated FoxO1 binds to ATG7 to trigger the autophagy machinery [63]. This discovery was unexpected, as under environmental conditions that favor autophagy induction, FoxO proteins are more likely present in the nucleus. In a follow-up study, they also found that FoxO3 could induce autophagy under the same settings but in a FoxO1-dependent way. It transcriptionally activates the expression of upstream regulator PIK3CA, which then results in FoxO1 phosphorylation and nuclear export [64]. In addition to general autophagy, FoxO3 is
involved in the regulation of mitophagy, an autophagy subtype that selectively targets mitochondria. This pathway is mediated by PINK1, a central mitophagy regulator and contributes to the redox homeostasis in the cells [65–67].

**FoxO regulation of other cellular pathways**

Other than autophagy and metabolism, FoxO transcription factors are also well known for their regulation in processes like cell cycle arrest, DNA damage repair, apoptosis and oxidative stress resistance. The activation of FoxO, either by transcriptional overexpression or pharmacologically targeting upstream regulators, resulted in a robust cell cycle arrest in cancer cell lines of colon carcinoma, glioblastoma, osteosarcoma, and acute T cell leukemia [68–70]. This FoxO-dependent proliferation regulation is mediated through transcription of multiple cell cycle kinase inhibitors like p27kip1 and downregulation of the expression of cyclin D1 and D2 [71–73]. In addition, FoxO3 can stimulate the expression of GADD45a or DDB1 for DNA damage repair during paused division [74, 75]. Besides cell cycle control, FoxO proteins are well-described inducers of apoptosis in different cell types. They can drive the expression of many pro-apoptotic genes including FASL, TRAIL, TNFR, BIM and BMF, leading to programmed cell death in both normal and cancer cells [76]. The importance of this function is implicated in the fact that a variety of cancers inactivate FoxO to promote their survival. In addition, FoxO proteins have also been intensively studied in their role of oxidative stress response. They act to enhance cellular detoxification via the induction of superoxide dismutase 2 (SOD2) and catalase expression. By protecting cells from ROS accumulation, FoxO reduces the risk of cancer development [77]. Other examples of FoxO functions include the negative regulation of RUNX2 by FoxO1 and FoxO4, which mitigated the migration and invasion of prostate cancer [78, 79]. Studies have also found that FoxO3 deficiency led to the activation of inflammatory NFκB pathway and increased tumor burden in mouse colon [80, 81].

**Physiological functions of FoxO**

**FoxO in aging and longevity**

**C. elegans**

In 1990s, longevity studies in *C. elegans* led to the identification of the insulin/insulin-like growth factor-1 signaling (IIS) pathway as the first established lifespan-regulating signaling pathway in animals [82]. To be specific, genetic mutations that nullify the activity of DAF-2, the invertebrate insulin/insulin-like growth factor-1 receptor, more than double the lifespan of the worms [83]. Mutants with reduced activity of the IIS signaling component AGE-1, the *C. elegans* homolog of mammalian PI3K, also exhibit extended longevity [84, 85]. Remarkably, the longevity phenotype associated with IIS reduction is completely dependent on DAF-16, the FoxO homolog in *C. elegans*. Over the past 20 years, other longevity-regulating factors have been reported and for many of them, their functions on aging require direct or indirect involvement of DAF-16 activity. Overexpression of JNK-1 or CST-1 promotes lifespan extension by phosphorylating and activating DAF-16 [86, 87]. The loss of RLE-1, an E3 ubiquitin ligase that catalyzes DAF-16 polyubiquitination, extends lifespan [88]. In contrast, the deubiquitylase MATH-33 stabilizes DAF-16 and its loss of function inhibits the longevity phenotype of daf-2 mutants [89]. In addition, transcription factors like HSF-1, SKN-1 and PQM-1 can function as cofactors for DAF-16 to synergistically mediate the extended lifespan induced by IIS inhibition [90–92]. Germline removal by laser microsurgery or genetic mutation of *glp-1* increases lifespan independent of IIS pathway but this benefit also relies on DAF-16 activity [93–96]. Although DAF-16 is not required for the lifespan extension effect of chronic calorie restriction in *eat-2* mutant [97], it is indispensable in longevity induced by calorie restriction in middle-aged worms or by intermittent fasting [98, 99]. At the molecular level, activation of DAF-16 by upstream signaling pathways leads to its translocation to the nucleus, where it binds to the chromosome and either activates or represses downstream genes in metabolism, autophagy, and stress response [100–102]. It is believed that the combined effects of DAF-16-mediated transcriptional changes leads to the lifespan extension in *C. elegans* [103].

**Drosophila**

Similar to worms, reduced IIS also promotes longevity in *Drosophila* and the extension of lifespan is dependent on the downstream transcription factor dFOXO, the fly homolog of FoxO and DAF-16 [104, 105]. However, unlike DAF-16, direct manipulation of dFOXO expression in certain tissues is sufficient to extend lifespan in *Drosophila*. Overexpression of dFOXO in adult *Drosophila* pericerebral fat body led to reduced neuronal expression of insulin-like peptides, as well as increased lifespan and fecundity [106, 107]. More recently, reduced IIS specifically in an astrocyte-like glia subtype was found to delay development and extend healthy lifespan in *Drosophila* in a dFOXO-dependent manner [108]. Although dFOXO is not required for the lifespan extension by dietary restriction [109], it mediates the negative effect of sugar-rich diet on longevity [110]. Mechanistically, studies have shown that increased fat storage and oxidative
stress resistance are implicated in dFOXO-mediated lifespan extension [104, 106].

**Mammals**

Multiple long-lived mouse models have been created by genetic manipulations targeting growth hormone, IGF-1, IGF-1 receptor, insulin receptor, and insulin receptor substrate [111–116]. However, some of the modifications also lead to negative changes like growth defects and insulin resistance [112, 116]. FoxO3 was reported to be required for lifespan extension under dietary restriction condition [117], but its implication in IIS inhibition-induced longevity or the overexpression phenotype have yet to be elucidated.

Several genetic variations within FOXO3 have been reported to be associated with human longevity in a number of geographical and ethnic groups [118–123]. These FOXO3 single nucleotide polymorphisms (SNPs) in long-lived men and women were associated with lower prevalence of cancer and cardiovascular diseases along with higher insulin sensitivity [118, 124]. A study on two intronic FOXO3 SNPs, rs12206094-T and rs4946935-A, revealed that both longevity-linked minor alleles are associated with enhanced promoter activity in cell-based assays and higher FOXO3 mRNA expression in many human tissues [125]. Another intronic FOXO3 SNP rs2802292 G-allele was also found to be associated with increased FOXO3 basal expression in population [126, 127]. It is proposed that these SNP-associated introns have a regulatory role on FOXO3 expression [128]. More work is needed before a causal relationship between FOXO3 and human longevity can be established.

**FoxO in brain development and CNS function**

The mammalian brain is made up of two basic types of cells: neurons and glia. Glia can be further categorized into more specific types based on their morphology and functions, such as astrocytes, microglia, and oligodendrocytes. Neurons are the key players in the brain that serve as information processors and messengers while the star-shaped astrocytes support neuronal functions through facilitating synaptic signaling, supplying energy and nutrition as well as stress resolution. Microglia are the immune cells in the brain. They patrol the brain and respond to inflammatory stimuli. Oligodendrocytes, on the other hand, wrap around neuronal axons to form myelin sheaths, speeding up the transmission of electrical impulses along the exons.

FoxOs, as versatile transcription factors mediating various cellular processes, play important roles in the brain both during development and in adult. FoxO proteins show differential expression patterns in adult mouse brains. FoxO1 is strongly expressed in dentate gyrus and the ventral CA regions of the hippocampus as well as in striatum, whereas FoxO3 is more diffusely expressed throughout the brain including all hippocampal areas, cortex and cerebellum. FoxO6 shows significant expression across hippocampus, the amygdalohippocampal area and the shell of the nucleus accumbens. The expression of FoxO4, however, is very limited in the brain [129–131]. Genetic deletion of Foxo genes in the mouse brain results in varied phenotypes. Germline Foxo3 null mice develop adult-onset auditory neuropathy making them partially deaf due to incorrectly positioned synapses within the cochlea [132]. Foxo6 knockout mice are capable of learning but have a reduced ability to form long-term contextual and object recognition memories, probably due to lower dendritic spine density in hippocampal neurons [133]. Brain-specific deletion of Foxo1 driven by the Nestin promoter results in increased anxiety in a forced swim test, contrary to the reduced anxiety in Foxo1-deficient mice [134]. Besides the neuronal phenotypes, ablation of Foxo1 using the Synapsin 1 promoter driven Cre in mice leads to a blunted refeeding response, increased sensitivity to leptin and amino acid signaling, and increased locomotor activity [135]. Its deletion in sympathetic nervous system results in reduced catecholamine biosynthesis, lower energy expenditure, improved glucose clearance and increased bone mass [136].

FoxO proteins are well recognized for their ability to integrate upstream stress signals to initiate fate-determination programs such as survival or apoptosis, and this is also applicable to neurons. It was shown that in PC12 cells or primary cultured neurons, FoxO3 regulates apoptosis upon nerve growth factor (NGF) deprivation [137]. Further studies suggested that this response is downstream of FasL and JNK signaling pathways [138]. FoxO1 is also involved in neuronal apoptosis downstream of NMDA receptor signaling by controlling the expression of TXNIP [139]. Moreover, MST1 can phosphorylate both FoxO1 and FoxO3 in cerebellar granule neurons under ROS or NGF withdraw to stimulate their transcriptional activity leading to cell death [87, 140]. In contrast, methylation of FoxO3 by methyltransferase SET9 impairs its activity and contributes to granule cell survival [141]. In addition, FoxO3 was found to mediate neuronal autophagy, the suppression of which via either genetic knockdown or expression of an upstream microRNA displayed neuroprotective effects upon traumatic brain injury (TBI) [142, 143]. Interestingly, mitochondrial FoxO3 was also detected in hippocampal neurons where it was proposed to confer protection against glutamate toxicity during epilepsy [144].

Neural stem cells (NSCs) in the brain are capable of self-renewal or giving rise to new neurons and certain types of glial cells. Adult NSCs are mostly localized to...
the subventricular zone (SVZ) and subgranular zone (SGZ) where they are under tight control of proliferation and differentiation throughout life [145]. Knockout of Foxo1/3/4 or Foxo3 alone is sufficient to reduce the quiescence of NSCs, causing them to hyper-proliferate and, as a consequence, results in the depletion of the stem cell pool early in life. These FoxO-deficient NSCs also exhibit other phenotypes like decreased self-renewal and increased apoptosis and high ROS levels [146–148]. In addition, new-born neurons lacking FoxO exhibits altered dendritic morphology, increased spine density and aberrant spine positioning [149]. Mechanistically, Schaffner and colleagues found that proper NSC differentiation requires the involvement of autophagy machinery and this process is FoxO dependent [149].

FoxO's function in the brain is not limited to neurons. FoxO3 was found to upregulate aquaporin 4 (AQP4), a water channel specifically expressed in astrocytes, to induce cerebral edema following TBI [150]. FoxO3 also keeps the astrocytes cell cycle in check and its expression significantly inhibits proinflammatory cytokine-induced astrocytes proliferation by activating cell cycle regulatory genes like p27kip1. Consistent with this observation, Foxo3-null mice exhibits severe astrogliosis [151]. In microglia, FoxO3 was shown to mitigate ROS by trans-activating antioxidant genes such as Sod2 and Cat, and this process is under the regulation of deacetylase sirtuin-3 (SIRT3) [152]. Moreover, it has been reported that FoxO1-mediated p27kip1 expression is indispensable for oligodendrocyte regeneration after neonatal hypoxia [153], while it is also responsible for nitric oxide-induced apoptosis in the oligodendroglial culture [154].

Recent work in our lab further delineated the cell-type specific role of FoxO3 in the brain [155]. We showed that in primary cultures, the subcellular localization of FoxO3 in astrocytes is highly sensitive to the changes of upstream insulin signaling but the same treatments triggered no response of FoxO3 translocation in neurons. Using conditional knockout and AAV-mediated rescue of FoxO3 expression in mice, we confirmed the cortical astrogliosis phenotype reported in Foxo3-null mice [151] and demonstrated that the phenotype can be attributed to the cell-autonomous function of FoxO3 in astrocytes. Additionally, FoxO3 deficiency altered the expression of a subset of lipid-regulatory genes and the overall lipid profile in the cortex. Using primary astrocyte cultures, we found that Foxo3 deletion not only impeded cellular ability to consume excess fatty acids, but also impaired mitochondrial function and blunted the capacity to uptake extracellular Aβ. All these dysfunctions could be rescued by astroglial AAV-FoxO3 overexpression. Given the critical role of astrocytes in maintaining brain homeostasis, loss of astrocytic FoxO3 may exacerbate neuronal vulnerability, particularly under pathological conditions such AD.

Role of FoxO in age-associated diseases

Type 2 diabetes mellitus

T2DM is a chronic metabolic disease that is most prevalent in older adults. In the past 20 years, the number of adults diagnosed with T2DM has more than doubled and it is currently the seventh leading cause of death in the United States. T2DM features hyperglycemia, insulin resistance and relative impairment in insulin secretion. The disease has both local and systematic manifestations and its pathophysiology closely involves FoxO. For example, the level and the subcellular localization of FoxO differ in pancreatic β cells at different stages of T2DM. Researchers observed predominantly inactive cytoplasmic FoxO1 in healthy β cells, but it is translocated to the nucleus in response to hyperglycemia. In advanced diabetes, FoxO1 disappears from β cells, accompanied with the loss of insulin signaling. It was proposed that FoxO1 preserves the balance of mitochondrial function by promoting the utilization of glucose over lipids. The dynamic behavior of FoxO1 reflects its role in mitigating β cell stress at an early stage but becomes exhausted when the disease proceeds [156–158]. Furthermore, FoxO is over-activated in many other organs including liver and skeletal muscles under insulin resistance conditions where it partakes clinical symptoms. Hepatic FoxO drives hyperglycemia by inducing the expression of G6Pase [159]. It can also promote hyperlipidemia by pushing the production and release of very low-density lipoprotein (VLDL)-triacylglycerol [34]. Moreover, FoxO's regulation on bile acids through CYP8B1 is disrupted, resulting in more 12α-hydroxylated bile acid secretion. 12α-hydroxylated bile acids are less potent than non-12α-hydroxylated bile acids at inhibiting triacylglycerol and cholesterol synthesis, which contributes to the atherogenic lipid profile in T2DM [53]. Studies have shown that induction of diabetes in mice causes muscle atrophy due to upregulated ubiquitin–proteasome and autophagy clearance. However, triple knockout of Foxo1/3/4 prevents the activation of protein degradation pathways and rescued the muscle loss [160].

Alzheimer’s disease

AD is the most common form of dementia in the elderly population. Patients experience progressive loss of memory and other cognitive abilities, which isolates them from family and society and eventually leading to death. AD is ranked as the sixth leading cause of death in the United States and costs 18.6 billion hours of care from unpaid caregivers in 2019, a contribution valued at nearly 244 billion dollars [161].
AD is pathologically characterized by the accumulation of extracellular senile plaques and intraneuronal neurofibrillary tangles (NFTs) in the brain. Senile plaques are aggregates of amyloid beta (Aβ) peptides while NFTs are mainly phosphorylated tau inclusions [162, 163]. Accordingly, two major hypotheses have emerged based on the pathologic hallmarks [164, 165]. Aβ is derived from amyloid precursor protein (APP) through sequential cleavage. APP processing through the amyloidogenic pathway requires two enzymes, β-secretase and γ-secretase, which subsequently cleave APP leading to the release of Aβ peptides (Fig. 4). Aβ is rapidly degraded under normal conditions, however, in aged individuals or under pathological conditions, the clearance capacity is impaired, resulting in Aβ accumulation and aggregation. Aβ_{40} and Aβ_{42} are two common species of Aβ peptides, with Aβ_{42} being more prone to aggregation. Increased production of Aβ_{42} or a rise in ratio of Aβ_{42}/Aβ_{40} from dysregulated cleavage often precede the formation of amyloid plaque. The amyloid hypothesis of AD pathogenesis proposed that the accumulated Aβ amyloid will develop into senile plaques, causing neurotoxicity and induction of tau pathology, eventually leading to neuronal cell death and neurodegeneration [166]. Alternatively, the tau hypothesis posits that the principal causative substance of AD is tau, a microtubule-associated protein that regulate the stability of tubulin assemblies. Hyperphosphorylated tau proteins under pathological conditions aggregate inside of neurons, disrupting the cellular homeostasis and causing neurodegeneration (Fig. 5). The amyloid hypothesis is strongly supported by the facts that amyloid deposits are a unique feature of AD and all identified genetic mutations in early-onset familial AD can be mapped to APP or presenilin 1/2, components of γ-secretase, and impact Aβ production. Nonetheless, the tau hypothesis agrees better with pathological staging of the disease and correlates with cognitive decline [166, 167]. The Aβ and tau pathologies trigger other neuropathological features that likely modulate disease progression. In particular, synaptic dysfunction and loss show the strongest correlation with

![Fig. 4 Proteolytic processing of APP. There are two distinct hydrolysis pathways in APP processing: amyloidogenic pathway (right) and non-amyloidogenic pathway (left). Sequential cleavage of APP by α-secretase and γ-secretase produces a soluble N-terminal peptide (sAPPα), a C-terminal APP intracellular domain (AICD) and a short fragment p3. This is the major secretory pathway with no Aβ production. On the other hand, cleavage by β-secretase and γ-secretase generates sAPPβ, AICD and Aβ [168, 169]. The cleavage sites of secretases are noted. The alternative cleavage of γ-secretase results in two Aβ species: Aβ_{40} and Aβ_{42}.

---

**Non-Amyloidogenic Pathway**

- APPSα
- β-secretase
- γ-secretase
- p3
- AICD
- α-CTF

**Amyloidogenic Pathway**

- APPSβ
- β-secretase
- γ-secretase
- Aβ
- AICD
- β-CTF

**Figure 4** Proteolytic processing of APP. There are two distinct hydrolysis pathways in APP processing: amyloidogenic pathway (right) and non-amyloidogenic pathway (left). Sequential cleavage of APP by α-secretase and γ-secretase produces a soluble N-terminal peptide (sAPPα), a C-terminal APP intracellular domain (AICD) and a short fragment p3. This is the major secretory pathway with no Aβ production. On the other hand, cleavage by β-secretase and γ-secretase generates sAPPβ, AICD and Aβ [168, 169]. The cleavage sites of secretases are noted. The alternative cleavage of γ-secretase results in two Aβ species: Aβ_{40} and Aβ_{42}.**
cognitive decline in AD patients. Neuroinflammation due to glial cell hyper-activation can impinge neuronal survival and function through secretion of toxic molecules and/or loss of trophic support.

Multiple studies implicate FoxO in AD pathophysiology although its exact role remains controversial. Several papers showed that FoxO proteins, especially FoxO3, mediate Aβ or AICD-induced apoptosis in primary cell cultures and in Drosophila, which leads to the loss of neurons or astrocytes [172–178]. FoxO3 has also been shown to be involved in Aβ-induced mitochondrial dysfunction in cultured neurons [179]. Qin and colleagues reported attenuation of amyloid pathology in a caloric restricted AD mouse model (Tg2576), and this is associated with activation of the insulin signaling pathway and down-regulation of FoxO3 [180]. However, other reports demonstrated a protective role of FoxO in the brain. FoxO has been shown to protect neurons against Aβ-induced toxicity by upregulating stress resistance genes [181, 182]. Moreover, Drosophila FoxO (dFOXO) is essential for the maintenance of autophagy in the fly brain, and its reduction during aging promotes Aβ-induced neuronal dysfunction [183]. Interestingly, in mouse and monkey models of T2DM, researchers observed that reduced FoxO activities correlated with elevated Aβ and phosphorylated tau level, implicating a connection of T2DM and AD through FoxO [184]. Shi and colleagues proposed a two-sided role of FoxO3, with it being neuroprotective in the beginning but neurotoxic at later stages in AD [185]. They found that FoxO3, as a direct target of CDK5, promoted survival in HT22 cells under glutamate treatment by upregulating the oxidative stress resistant gene Sod2 while it switched to a proapoptotic pathway after prolonged exposure in a BIM- and FASL-dependent manner. FoxO3 also mediated the glutamate induced Aβ production and consistently, the authors found activation and upregulation of FoxO3 in hippocampal neurons precede neurodegeneration and plaque formation in p25 transgenic mice [185].

Our study of FoxO3 in the 5xFAD mouse model supports a beneficial role of astrocytic FoxO3 against the amyloid pathology [155]. We found that Nestin-Cre mediated conditional knockout of Foxo3 in 5xFAD mice significantly aggravated the plaque burden in the cortex compared to the littermate 5xFAD control. Increased plaque pathology was accompanied by enhanced synaptic loss and reduced recruitment of reactive astrocytes to the plaque location. Surprisingly, we also observed a blunted response of reactive microglia in the proximity of plaques. In contrast, AAV-mediated astrocyte-specific expression of FoxO3 in 5xFAD mice ameliorated the cortical plaque load, enhanced synapse number and also...
promoted the recruitment of both astrocytes and microglia to the plaques. Taken together, these results suggest that astrocytic FoxO3 modulates amyloid pathology through both a cell-autonomous effect and by influencing the recruitment of plaque-associated microglia.

### Other neurodegenerative diseases

In addition to AD, FoxO has been implicated in other neurodegenerative diseases like Parkinson's disease (PD) and Huntington's disease (HD). PD affects predomi-
nately dopaminergic neurons in the substantia nigra, and its symptoms include tremor, bradykinesia, limb rigidity and balance problems. During the course of PD, α-synuclein aggregates and accumulates in affected neu-
rons to form Lewy bodies and ultimately causes neuronal death. Researchers have shown opposing roles of FoxO3 in dopaminergic neurons expressing α-synuclein. On the one hand, expression of a constitutively active form of FoxO3 induced degradation of α-synuclein and clearance of defective mitochondria. On the other hand, dominant negative forms of FoxO3 protected against death of dopaminergic neurons [186, 187]. Thus, while FoxO3 can protect cells from α-synuclein toxicity, it may also be responsible for neuronal death. In a rat model of PD, FoxO3 was found to inhibit the apoptosis in nigral dopaminergic neurons in a CDKN2D-dependent manner [188]. Likewise, the dFOXO function varies in different PD models in Drosophila. It ameliorates the mitochondrial defects and neuronal degeneration in PINK1 null mutants while contributes to dopaminergic neurodegeneration in LRRK2-linked PD [189, 190].

HD is an autosomal dominant disease caused by an expanding poly-Q tract in the huntingtin (HTT) protein. It features abnormal involuntary movements, cognitive decline, and psychiatric disorders. Similar to the AD and PD studies, there are contrasting reports on FoxO's role in HD. FoxO3 has been shown in some studies to stimulate HD progression [191–193], whereas in other studies HD development was alleviated by FoxO [194, 195]. It is possible that the influence of FoxO3 activity differs with different stages of the disease. Interestingly, Vidal and colleagues unveiled a new mechanism of FoxO function in HD, where the loss of the unfolded protein response (UPR) transcription factor XBP1 leads to augmented expression of FoxO1, thus promoting autophagy and mutant HTT clearance [196]. Altogether, the published literature support a prominent role of FoxO in AD and other neurodegenerative diseases. However, its effect is likely dynamic and cell type-, context- and disease stage-dependent, which may explain the distinct and opposite results observed. Additional studies are needed to elucidate the underlying mechanisms and functional outcomes of FoxO in these diseases.

### Summary and perspectives

Aging is a complex process, and so are age-related diseases. FoxO transcription factors play a crucial role in both aging and age-related diseases, and thus could potentially serve as an underlying molecular link. Intriguingly, certain features of FoxO we learned from aging studies are consistent with those observed in disease context. For example, in C. elegans and Drosophila, the lifespan extension exerted by FoxO is likely the result of a combined autocrine and paracrine effects. DAF-2 is believed to primarily function in the nervous system. Mosaic worms with daf-2 deficiency in a neuronal lineage and epidermis showed significantly increased lifespan [197]. In addition, expression of daf-2 using neural promoters normalized the lifespan of daf-2 mutants to control levels [198]. However, expression of daf-16 in neurons only achieved 5–20% of lifespan extension in daf-16; daf-2 animals. In contrast, restoration of DAF-16 activity in intestine, which is also the worm's adipose tissue, is sufficient to extend their lifespan by 50–60% and it can also completely rescue the longevity defect of daf-16 germine mutants [199]. Similarly, in Drosophila, limited activation of dFOXO in pericerebral fat body reduced the insulin-like peptide synthesis in neurons, and thus increases the lifespan of the animal [106]. It is possible that FoxO activity modulates lipid metabolism in these lipid storing cells, which in turn influence neuronal endo-
crine processes and lifespan in a non-cell autonomous manner. Strikingly, in mouse CNS, we found FoxO3 deficiency disrupts lipid metabolism in astrocytes, the glial cells which store and catabolize most lipids in the brain. In an amyloid mouse model, we showed that astrocytic FoxO3 not only function cell-autonomously, but also recruit microglia to engage amyloid plaques [155]. Although how FoxO3's function in astrocytes affects cell–cell communication awaits further investigation, this interaction resembles what is observed in aging studies. Besides astrocyte-microglia interaction, it would also be interesting to understand whether astrocytic FoxO3 communicate with neurons and how these intercellular crosstalk modulate neuronal function and amyloid and tau/NFT pathology.

Accumulating evidence supports the existence of a shared risk for AD and T2DM [200]. The pathogenesis of AD is accompanied by significant disruption of meta-
boic pathways in the CNS. For example, AD brains suffer from oxidative stress and impaired glucose metabolism [201], and they take on features of insulin resistance [202, 203]. In addition, AD patients were found to carry more extensive islet amyloid, a pathogenic feature of T2DM,
than non-AD controls [204]. Further, multiple reports implicate T2DM as a risk factor for AD development. Research in rodents demonstrated AD-like neuropathology in T2DM models and accelerated pathology development in AD models with T2DM-like metabolic changes induced by high-fat diet [205–209]. However, how peripheral insulin resistance modulates the central insulin signaling remains controversial. Studies in murine and primate models of T2DM showed an upregulated insulin signaling in affected brain, implying decreased FoxO activity under this condition [184]. We have shown that CNS FoxO3 deficiency leads to aggravated cortical amyloid pathology [155]. It has also been reported that FoxO mitigates β cell stress in early T2DM but such an effect is blunted when the disease proceeds [156, 157]. Age-associated decline of FoxO expression correlates with higher incidence of age-related diseases in the elderly population [155, 210]. Thus, proper levels of FoxO activity may be important not only for lifespan regulation but also confer protection against age-related diseases. Upregulation of FoxO activity thus holds therapeutic promise in the prevention or treatment of these age-related diseases. The fact that FoxO can be modulated by phosphorylation and other PTMs makes it an attractive target drugable by small chemicals. However, due to the complexity of the FoxO regulation and function, the level, site and duration of FoxO need to be tightly controlled. Therefore, in-depth understanding of each FoxO protein under different physiological and pathological conditions at molecular, cellular, and functional levels are needed to decipher their role in aging and disease to inform the development of future therapeutics.

Abbreviations

T2DM: Type 2 diabetes mellitus; AD: Alzheimer’s disease; C. elegans: Caenorhabditis elegans; DBD: DNA-binding domain; DBE: DAF-16 family member; binding element; IRE: Insulin responsive element; PTMs: Post-translational modifications; NLS: Nuclear localization signal; NES: Nuclear export signal; TAD: Transactivation domain; IGFs: Insulin-like growth factors; IRS: Insulin receptor substrate; P3K: Phosphatidylinositol 3-kinase; PIP3: Phosphatidylinositol (3,4,5)-trisphosphate; PDK1: Phosphoinositide-dependent kinase 1; POR: Protein kinase B; ROS: Reactive oxygen species; JNK: C-Jun N-terminal kinase; AMPK: AMP-activated protein kinase; CDKs: Cyclin-dependent kinases; ATM: Ataxia telangiectasia mutated; ATR: ATM Rad3-related; HDACs: Histone deacetylases; SKP2: S-phase kinase associated protein 2; MDM2: Mouse double minute 2 homolog; PRMT1: Protein arginine methyltransferase 1/6; OGT: O-GlcNAc transferase; G6Pase: Glucose-6-phosphatase; PEPCK: Phosphoenolpyruvate carboxykinase; PDK4: Pyruvate dehydrogenase kinase 4; SRREBP1c: SREBP1c; Scd1: Stearyl-CoA desaturase; LPL: Lipoprotein lipase; CPT1: Carnitine palmitoyltransferase-1; FAT: Fatty acid transacylase; LDLR: Low-density lipoprotein receptor; PCSK9: Proprotein convertase subtilisin/kexin type 9; LDLR: LDL receptor; POMC: Proopiomelanocortin; AgRP: Agouti-related peptides; ARC: Arcuate nucleus; ATG: Autophagy-related; SOD2: Superoxide dismutase 2; IRS: Insulin/insulin-like growth factor-1 signaling; B DH: Dopamine-b-hydroxylase; NGF: Nerve growth factor; CGNs: Cerebellar granular neurons; TRB: Traumatic brain injury; NSCs: Neural stem cells; SVZ: Subventricular zone; SGZ: Subgranular zone; AQP4: Aquaporin 4; SIRT3: Deacetylase sirtuin-3; VLDL: Very low density lipoprotein; NFTs: Neurofibrillary tangles; Aβ: Amyloid beta; APP: Amyloid precursor protein; AICD: APP intracellular domain; PD: Parkinson’s disease; HD: Huntington’s disease; HTT: Huntington; UPR: Unfolded protein response.

Acknowledgements

We thank members of the Zheng laboratory for suggestions and edits.

Authors’ contributions

SD and HZ discussed and approved the overall structure of the review. SD wrote the first draft and prepared the figures. Additional drafts were written by SD and HZ. Both authors read and approved the final manuscript.

Funding

This work was supported by grants from the NIH (RF1 AG057509, R01 AG057509, R01 AG020670, RF1 AG062257 and P01 AG066606 to HZ). The authors declare that they have no competing interests.

Received: 16 October 2021 Accepted: 20 October 2021 Published online: 02 November 2021

References

1. Obsil T, Obsilova V. Structural basis for DNA recognition by FOXO proteins. Biochim Biophys Acta. 2011;1813(11):1946–53.
2. Ma J, Matkar S, He X, Hua X. FOXO family in regulating cancer and metabolism. Semin Cancer Biol. 2018;50:32–41.
3. Pienakova K, Kohoutova K, Obsilova V, Ausserlechner MJ, Veverka V, Obsil T. Forkhead domains of FOXO transcription factors differ in both overall conformation and dynamics. Cells. 2019. https://doi.org/10.3390/cells8090966.
4. Paradis S, Ruvkin G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev. 1998;12(16):2488–98.
5. Lin K, Hsin H, Libina N, Kenyon C. Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling. Nat Genet. 2001;28(2):139–45.
6. Kramer JM, Davidge JT, Lockyer JM, Staveley BE. Expression of Drosophila FOXO regulates growth and can phenocopy starvation. BMC Dev Biol. 2003;3:5.
7. Junger MA, Rintelten F, Stocker H, Wasserman JD, Vegh M, Radimeniski T, Greenberg ME, Hafen E. The Drosophila forkhed transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J Biol. 2003;2(3):20.
8. Kang P, Chang K, Liu Y, Bouska M, Birnbaum A, Karashchuk G, Thakore R, Zheng W, Post S, Brent CS, et al. Drosophila Kruppel homolog 1 represses lipolysis through interaction with dFOXO. Sci Rep. 2017;7(11):16369.
9. Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance and aging. Circ Res. 2012;110(9):1238–51.
10. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007;8(6):440–50.
11. Bridge D, Theedfils AG, Holler RL, Marcinkevicius E, Steele RE, Martinez DE. FoxO and stress responses in the nidavian Hydra vulgaris. PLoS ONE. 2010;5(7):e11686.
12. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The energy sensor AMP-activated protein kinase directly
regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007;282(41):30107–19.

13. Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, Konishi Y, Schafer EM, Bonni A. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science. 2008;319(5870):1665–8.

14. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006;314(5797):294–7.

15. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solomin N, Lernenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein network responses to DNA damage. Science. 2007;316(5828):1160–6.

16. Beharry AW, Sandersa PB, Roberts BM, Ferreira LF, Senf SM, Judge AR. HDAC1 activates FOXO and is both sufficient and required for skeletal muscle atrophy. J Cell Sci. 2014;127(Pt 7):1441–53.

17. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 2005;102(5):1649–54.

18. Yang J, Yang Z, Csik S, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10(2):138–48.

19. Brenkman AB, de Keizer PL, van den Broek NJ, Jochemsen AG, Burgering BM. Mdm2 induces mono-ubiquitination of FOXO4. PLoS ONE. 2008;3(7):e2819.

20. Yamagata K, Nakal K, Takahashi Y, Namiki K, Hisatake K, Kako K, Muka H, Kasuya Y, Fukamizu A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell. 2008;32(2):221–31.

21. Kuo M, Zibberferb V, Gangneux N, Christeff N, Issad T, O’GlicAc: modification of FOXO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon? Biochem. 2008;90(5):679–85.

22. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for neurons. Science. 2008;319(5870):1665–8.

23. Bonni A. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons significantly impacts on glucose metabolism through downregulation of glucokine expression and upregulation of glycolysis. PLoS ONE. 2013;8(8):e74340.

24. Lee S, Dong HH. FOXO integration of insulin signaling with glucose and lipid metabolism. J Endocrinol. 2017;232(1):R67–79.

25. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6(3):208–16.

26. Patel PV, Patel HK, Panchal SS, Mehta TA. Self micro-emulsifying drug delivery system of tacrolimus: formulation, in vitro evaluation and stability studies. Int J Pharm. 2013;32(3):295–301.

27. Xiong X, Tao R, DePinho RA, Dong XC. Deletion of hepatic Foxo1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of glucokine expression and upregulation of glycolysis. Biochim. 2003;375(3):235–45.

28. Os I, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR, Schwartz MW, et al. FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 2015;6:7079.

29. Furuya T, Kitayama K, Yasahita H, Mori N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem. 2003;375(2):365–71.

30. Kamei Y, Mizukami J, Miura S, Suzuki M, Takahashi N, Kawada T, Taniguchi T, Ezaki O. A forkhead transcription factor FKHR up-regulates lipoprotein lipase expression in skeletal muscle. FEBS Lett. 2003;536(1–3):232–6.

31. Link W, Fernandez-Marcos PJ. FOXO transcription factors at the interface of metabolism and cancer. Int J Cancer. 2017;141(12):2379–91.

32. Deng X, Zhang W, Os I, Williams JB, Dong Q, Park EA, Raghow R, Unterman TG, Elam MB. FOXO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem. 2012;287(24):23122–43.

33. Hauser SA, Han S, Accili D. Hepatic FOXO1 ablation exacerbates lipid abnormalities during hyperglycemia. J Biol Chem. 2010;285(35):26861–8.

34. Zhang W, Patel S, Chauhan B, Guo S, Powell DR, Le J, Klotzas A, Matika R, Xiao X, Franks R, et al. FOXO1 regulates multiple metabolic pathways in the liver: effects on glucokinogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 2006;281(15):10105–17.

35. Xiong X, Tao R, DePinho RA, Dong XC. The autophagy-related gene 14 (Atg14) is regulated by forkhead box O transcription factors and circadian rhythms and plays a critical role in hepatic autophagy and lipid metabolism. J Biol Chem. 2012;287(46):39107–14.

36. Dong XC. FOXO transcription factors in non-alcoholic fatty liver disease. Liver Res. 2017;1(3):168–73.

37. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoc-III and triglyceride metabolism. J Clin Invest. 2004;114(10):1493–503.

38. Gross DN, van den Heuvel AP, Birmbaum MJ. The role of Foxo in the regulation of metabolism. Oncogene. 2008;27(16):2320–36.

39. Bastie CC, Nahle Z, Mcloughlin T, Esser K, Zhang W, Unterman T, Abumrad NA. FOXO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and –independent mechanisms. J Biol Chem. 2005;280(14):14222–9.

40. Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6. J Lipid Res. 2013;54(10):2745–53.

41. Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. FOXO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013;288(41):29252–9.

42. Li T, Ma H, Park YJ, Lee YK, Strom S, Moore DD, Chiang JY. Forkhead box transcription factor O1 inhibits cholesterol 7α-hydroxylase in human hepatocytes and in high fat diet-fed mice. Biochim Biophys Acta. 2009;1791(9):991–105.

43. Hantes RS, Pratt-Hyatt W, Welch CL, Claassen SD, Accili D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2012;15(1):165–74.
54. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–71.

55. Bagrodia D, Lu YX, Kaelin GB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J Neurosci. 1999;19(18):RC26.

56. Fukuda M, Jones JE, Olson D, Hill J, Lee CE, Gautron L, Choi M, Zigman SW, Kim HS, Park JY, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci. 2006;9(7):901–6.

57. Sasaki T, Kitamura T, Roles of Foxo1 and Sirt1 in the central regulation of food intake. Endocr J. 2010;57(1):59–66.

58. Parzych KR, Klossky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2014;20(3):460–73.

59. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L, Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, You H. FOXO3a-dependent mechanism, and regulation. Antioxid Redox Signal. 2014;20(3):460–73.

60. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999;399(6734):857–68.

61. Kops GJ, Medema RH, Glassford J, Essers MA, DiBacco S, de Jonge ILM. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer. PLoS ONE. 2014;9(7):e101411.

62. Kenyon C. The first long-lived mutants: discovery of the insulin/IGF-1 pathway for ageing. Philos Trans R Soc Lond B Biol Sci. 2011;366(1561):9–16.

63. Kenyon C, Zhang J, Gensch E, Rudner A, Tissenbaum H. A. elegans mutant that lives twice as long as wild type. Nature. 1993;366(6454):461–6.

64. Kops GJ, Medema RH, Johnson TE. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genet. 1988;118(1):75–86.

65. Friedman DB, Johnson TE. Three mutants that extend both mean and maximum life span of the nematode, Caenorhabditis elegans, define the age-1 gene. J Gerontol. 1988;43(4):B102-109.

66. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Davis RL, Tissenbaum HA. JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor DAF-16. Proc Natl Acad Sci USA. 2005;102(12):4494–9.

67. Hsin H, Kenyon C. Signals from the reproductive system regulate the life span of the nematode, Caenorhabditis elegans. Cell. 2006;124(5):1055–68.

68. Tepper RG, Ashraf J, Kaleytsch R, Blekas M, Tissenbaum HA. PQM-1 complements DAF-16 as a key transcriptional regulator of lifespan. Science. 2008;320(5878):1025–8.

69. Berman JR, Kenyon C. Germ-cell loss extends C. elegans life span through regulation of DAF-16 by kri-1 and lipophilic-hormone signaling. Genes Dev. 2013;27(15):1472–6.

70. Apfeld J, O’Conner G, McDonagh T, DiStefano PS, Curtis R. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. 2004;18(24):3062–9.

71. Greer EL, Dowlatshahi H, McDonald TE. FOXO pathway in human epithelial cells. J Biol Chem. 2003;278(21):18124–37.

72. Fu Z, Tindall DJ. FOXO3a in cancer and regulation of apoptosis. Oncogene. 2006;27(16):2312–9.

73. Coomans de Brachene A, Demoulin JB. FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci. 2016;73(6):1159–72.

74. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H. FOXO1 inhibits RuntX2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 2011;71(9):3257–67.

75. Du and Zheng Cell Biosci (2021) 11:188

Page 14 of 17
99. Honjoh S, Yamamoto T, Uno M, Nishida E. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature. 2009;457(7230):726–30.

100. Lee SS, Kennedy S, Tonolen AC, Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science. 2003;300(5619):644–7.

101. Melendez A, Tallozy C, Seaman M, Eskelinen EL, Hall DH, Levine B. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science. 2003;301(5638):1387–91.

102. Murphy CT, Mccarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H. Kenyon's genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424(6946):277–83.

103. Uno M, Nishida E. Lifespan-regulating genes in C. elegans. NPJ Aging Mech Dis. 2016;1(1):1603.

104. Giannakou ME, Partridge L. Role of insulin-like signalling in Drosophila melanogaster. Cell Biol. 2007;52(1):70–85.

105. Yamamoto R, Tatar M. Insulin receptor substrate chico acts with the choiceness and conservation of insulin signaling in C. elegans. Nature. 2003;300(5619):636–9.

106. Hwangbo DS, Gershman B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO gene is required for life-span and fertility. Aging Cell. 2008;7(4):460–72.

107. Giannakou ME, Goss M, Junger MA, Hafen E, Leevers SJ, Partridge L. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Aging Cell. 2005;4(3):235–44.

108. Wooding NS, Rajasingam A, Minkley LJ, Rizzo A, Partridge L. Independent glial subtypes delay development and extend healthy lifespan upon reduced insulin-PI3K signalling. BMC Biol. 2020;18(1):124.

109. Giannakou ME, Goss M, Partridge L. Role of dFOXO in lifespan extension by dietary restriction in Drosophila melanogaster: not required, but its activity modulates the response. Aging Cell. 2008;7(2):187–98.

110. Dobson AJ, Ezcurra M, Fanagan CE, Summerfield AC, Piper MDW, GEMS D, Alic N. Nutritional programming of lifespan by FOXO inhibition on sugar-rich diets. Cell Rep. 2017;18(2):299–306.

111. Kim SS, Lee CK. Growth signalling and longevity in mouse models. BMB Rep. 2019;52(1):70–85.

112. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci USA. 2001;98(12):6766–41.

113. Lorenzini A, Salmon AB, Lerner C, Torres C, Ikeno Y, Motch S, McCarter R, Christiansen L. Replication of an association of variation in the FOXO3A gene with human longevity. Proc Natl Acad Sci USA. 2014;111(8):2700–5.

114. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Nelson JF, Strong R, Bokov A, Diaz V, Ward W. Probing the relationship between insulin sensitivity and longevity using genetically modified mice. J Gerontol A Biol Sci Med Sci. 2012;67(12):1332–8.

115. Furuyama T, Nakazawa T, Nakano I, Mori N. Identification of the differential distribution patterns of mRNAs and conserved binding sequences for mouse DAF-16 homologues. Biochem J. 2000;349(Pt 2):629–34.

116. Biggs WH 3rd, Cavenue W, Arden KC. Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome. 2001;12(6):411–24.

117. Hoekman MF, Jacobs FM, Smidt MP, Burbach JP. Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Exp Patterns. 2006;6(2):134–40.

118. Gilels F, Paquette ST, Zhang J, Rahman I, White PM. Mutation of FoxO3 causes adult onset auditory neuropathy and alters cochlear synapse architecture in mice. J Neurosci. 2013;33(47):18409–24.

119. Papadia S, Hu D, Huntsman S, Sung A, Chu C, Chen J, Joyner AH, Faida J, Schork N, Huesle WC, Reiner AP, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009;8(4):460–72.

120. Morris BJ, Chen R, Donlon TA, Evans DS, Tranah GJ, Parini N, Ehret GB, Newton-Chew C, Seto T, Willcox DC, et al. Association analysis of FOXO3 longevity variants with blood pressure and essential hypertension. Am J Hypertens. 2016;29(11):1292–300.

121. Kajimura D, Paone R, Mann JJ, Karsenty G. Foxo1 regulates Dbh expression in mice. J Biol Chem. 2010;285(37):28307–18.

122. Lazzarotto M, Caruso S, Calvani A, Gualberto F, Mencarelli P, Ceccarelli M, Serrano M, Mencarelli P, Ceccarelli M, Serrano M, Mencarelli P, Ceccarelli M, Serrano M. Identification of the differential distribution patterns of mRNAs and conserved binding sequences for mouse DAF-16 homologues. Biochem J. 2000;349(Pt 2):629–34.

123. Papadaki S, Soriani FX, Leveille F, Martel MA, Dakin KA, Hansen HH, Kandil A, Sinfrenger M, Fowler J, Stefioska V, et al. Synthetic NHLDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci. 2008;11(4):476–87.

124. Yuan Z, Lehtinen MK, Merlo P, Villen J, Gygi S, Bonni A. Regulation of neuronal cell death by MST1-FOXO1 signaling. J Biol Chem. 2009;284(17):11285–92.

125. Liu Q, Hao Y, Tao L, Peng S, Rao C, Chen H, You H, Dong MQ, Yuan Z. Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death. EMBO Rep. 2012;13(4):371–7.

126. Sun L, Zhao M, Liu M, Su P, Zhang J, Li Y, Yang X, Wu Z. Suppression of FoxO3a attenuates neurobehavioral deficits after traumatic brain
injury through inhibiting neuronal autophagy. Behav Brain Res. 2018;337:271–9.

143. Sun L, Zhao M, Wang Y, Liu A, Lv M, Li Y, Yang X, Wu Z. Neuroprotective effects of mif-27a against traumatic brain injury via suppressing FoxO3-mediated neuronal autophagy. Biochem Biophys Res Commun. 2017;482(4):1141–7.

144. Caballero-Caballero A, Engel T, Martinez-Villarreal J, Sanz-Rodriguez A, Renault VM, Rafalski VA, Morgan AA, Salih DA, Brett JO, Webb AE, Villeda Paik JH, Ding Z, Narurkar R, Ramkissoon S, Muller F, Kamoun WS, Chae Rangarajan P, Karthikeyan A, Lu J, Ling EA, Dheen ST. Sirtuin 3 regulates Jablonska B, Scafidi J, Aguirre A, Vaccarino F, Nguyen V, Borok E, Horvath Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, Accili D. FoxO1 Buteau J, Shlien A, Foisy S, Accili D. Metabolic diapause in pancreatic Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor O'Neill BT, Bhardwaj G, Penniman CM, Krumpoch MT, Suarez Beltran PA, Alzheimer's Association. 2020 Alzheimer's disease facts and figures. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82(12):4245–9.

146. Wang S, Zhao Y, Wang L, Wang J, Duan X. Post traumatic stress. Mol Psychiatry. 2010;15(11):1046–52.

147. Kamitani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease. Front Neurosci. 2018;12:25.

148. Manolopoulos KN, Klotz LO, Korsten R, Bornstein SR, Barthel A. Linking Alzheimer's disease to insulin resistance: the FOXO response to oxidative stress. Mol Psychiatry. 2010;15(11):1046–52.

149. Thathiah A, De Strooper B. The role of G protein–coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci. 2011;12(2):73–87.

150. Vetrivel KS, Thnakinagar G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurochemistry. 2006;66(2 Suppl 1):S69-73.

151. Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133(5):655–60.

152. Verwilj P, Kim HS, Kim S, Kang J, Kim S. Shedding light on tau protein aggregation: the progress in developing highly selective fluorophores. Chem Soc Rev. 2018;47(7):2249–65.

153. Wang X, Wang Z, Chen Y, Huang X, Hu Y, Zhang R, Ho MS, Xu L. FoxO mediates APP-induced AICD-dependent cell death. Cell Death Dis. 2014;5: e1233.

154. Sanphu P, Biswas SC. FoxO3a is activated and executes neuron death via Bim in response to beta-amyloid. Cell Death Dis. 2013;4; e625.

155. Akhter R, Sanphu P, Biswas SC. The essential role of p53-upregulated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in beta-amyloid-induced neuron death. J Biol Chem. 2014;289(15):10812–22.

156. Wong HK, Veremeyko T, Patel N, Lemere CA, Eau C, Vanderburg C, Kirchveky AM. De-repression of FoxO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet. 2013;22(15):3077–92.

157. Nuzzo D, Picone P, Baldassano S, Caruana L, Messina E, Marino Gamazzza A, Cappello F, Mule D, Carlo M. Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. Curr Alzheimer Res. 2015;12(8):723–35.

158. Fernandez AM, Hervas R, Dominguez-Fraile M, Garrido VN, Gomez-Gutierrez P, Vega M, Vitorica J, Perez JJ, Torres Almen I. Blockade of the interaction of calcineurin with FOXO in astrocytes protects against amyloid-beta-induced neuronal death. J Alzheimers Dis. 2016;52(4):1471–8.

159. Saha P, Biswas SC. Amyloid-beta induced astrocytosis and astrocyte death: implication of FoxO3a-Bim-caspase3 death signaling. Mol Cell Neurosci. 2015;68:203–11.

160. Shi C, Zhu J, Leng S, Long D, Luo X. Mitochondrial FoxO3a is involved in amyloid beta peptide-induced mitochondrial dysfunction. J Bioenerg Biomembr. 2016;48(3):189–96.

161. Qin W, Zhao W, Ho L, Wang J, Walsh K, Gandy S, Pasinetti GM. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann NY Acad Sci. 2008;1147:335–47.

162. Guo P, Wang D, Wang X, Feng H, Tang Y, Sun R, Zheng Y, Dong L, Zhao J, Zhang X, et al. Effect and mechanism of fuzhisan and donepezil on the sirtuin 1 pathway and amyloid precursor protein metabolism in PC12 cells. Mol Med Rep. 2016;13(4):3539–46.

163. Lin CL, Huang WN, Li HH, Huang CN, Hsieh S, Lai C, Lu FJ. Hydrogen-rich water attenuates amyloid beta-induced cytotoxicity through upregulation of Sirt1-FoxO3a by stimulation of AMP-activated protein kinase in SK-N-MC cells. Chem Biol Interact. 2015;240:12–21.

164. Omata Y, Lim YM, Akao Y, Tsuda L. Age-induced reduction of sirtuin 1 and amyloid precursor protein expression in Abeta1-40/42 and phospho-tau may abet alzheimer development. J Neurochem. 2018;143(3):313–26.
186. Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, Schneider BL. FOXO3 determines the accumulation of alpha-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet. 2014;23(6):1435–52.

187. Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci. 2014;39(4):159–69.

188. Liu YY, Zhang YN, Yang QS. Downregulated expression of microRNA-329 inhibits apoptosis of nigral dopaminergic neurons by regulating CDRN2D expression via the FoxO3a signaling pathway in rats with Parkinson’s disease. J Cell Physiol. 2018;233(1):8617–29.

189. Koh H, Kim H, Kim MJ, Park J, Lee HJ, Chung J. Silent information regulator 2 (Sir2) and Forkhead box O (FOXO) complement mitochondrial dysfunction and dopaminergic neuron loss in Drosophila PTEN-induced kinase 1 (PINK1) null mutant. J Biol Chem. 2012;287(16):12750–8.

190. Kanaci T, Sawada T, Davies SA, Ichinose H, Hasegawa K, Takahashi R, Hatton N, Imai Y. The nitric oxide-cyclic GMP pathway regulates FoxO and alters dopaminergic neuron survival in Drosophila. PLoS ONE. 2012;7(2):e30958.

191. Davila D, Torres-Alemán I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell. 2008;19(S):2014–25.

192. Bahia PK, Pugh V, Hoyland K, Hensley V, Rattray M, Williams RJ. Neuroprotective effects of phenolic antioxidant tBHQ associate with inhibition of FoxO3a nuclear translocation and activity. J Neurochem. 2012;123(1):182–91.

193. Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN, Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Apfeld J, Kenyon C. Cell nonautonomy of FOXO in the regulation of diapause and life span. Cell. 2011;146(1):153–8.

194. Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Kiffin R, Segura-Aguilar J, Cao D, Lu H, Liu Y, Neve RL, Taylor JP, Driscoll M, et al. FOXO3 is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci. 2009;29(25):8236–47.

195. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, et al. Neuroprotective role of Sir2 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets. Nat Med. 2011;17(1):153–8.

196. Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Kiffin R, Segura-Aguilar J, Cuoero AW, et al. Targeting the UPR transcription factor XBP1 protects against Huntington’s disease through the regulation of FOXO1 and autophagy. Hum Mol Genet. 2012;21(10):2245–52.

197. Apfeld J, Kenyon C. Cell nonautonomy of C. elegans daf-2 function in the regulation of diapause and life span. Cell. 1998;95(2):199–210.

198. Wolkom CA, Kimura KD, Lee MS, Ruvkun G. Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science. 2000;290(5489):147–50.

199. Libina N, Berman JR, Kenyon C. Tissue-specific activities of C. elegans DAF-16 in the regulation of lifespan. Cell. 2003;115(4):489–502.

200. Jayaraman A, Pike CJ. Alzheimer’s disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep. 2014;14(4):476.

201. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148–60.

202. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.

203. Moloney AM, Griffin RL, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224–43.

204. Janson J, Laerdcke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2):474–81.

205. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007;56(7):1817–24.

206. Jung HJ, Kim YJ, Eggert S, Chung KC, Choi KS, Park SA. Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. Exp Neurol. 2013;248:441–50.

207. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009;150(12):5294–301.

208. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambarei G, Rocher A, Mobbs CV, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004;18(7):902–4.

209. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2007;282(50):36275–82.

210. Birnbaum A, Wu X, Taras M, Liu N, Bai H. Age-dependent changes in transcription factor FOXO targeting in female Drosophila. Front Genet. 2019;10:312.